Next Science Ltd
ASX:NXS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.125
0.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Next Science Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | AU |
Market Cap | 39.4m AUD |
Net Margin |
-58%
|
Country | JP |
Market Cap | 6.8T JPY |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.9B CHF |
Net Margin |
12%
|
Country | DK |
Market Cap | 200.9B DKK |
Net Margin |
19%
|
Country | US |
Market Cap | 16.9B USD |
Net Margin |
11%
|
Country | KR |
Market Cap | 9.9T KRW |
Net Margin |
-358%
|
Country | CA |
Market Cap | 6.9B USD |
Net Margin |
-8%
|
Country | CN |
Market Cap | 48.6B CNY |
Net Margin |
42%
|
Country | US |
Market Cap | 6.3B USD |
Net Margin |
29%
|
Country | US |
Market Cap | 6.1B USD |
Net Margin |
9%
|
Country | UK |
Market Cap | 4.8B GBP |
Net Margin |
7%
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Next Science Ltd's most recent financial statements, the company has Net Margin of -57.9%.